A reproducible model of acute hepatic failure by transient ischemia in the pig

https://doi.org/10.1016/0022-4804(87)90070-9Get rights and content

Abstract

A model of transient acute hepatic failure has been developed in the pig. Three days after a functional end-to-side protacaval shunt was introduced, 15 ambulant animals underwent total liver ischemia for 4 to 6 h by the closure of a mechanical clamp surrounding the hepatic artery. Four of the eight animals subjected to 4 hr of ischemia survived. All but one of the animals undergoing 6 hr of hepatic ischemia developed grade 4 encephalopathy after 24 to 30 hr and died within 50 hr. Quantitative estimation of liver cell necrosis revealed less than 40% necrosis in the survivors, and approximately 62% (range 49–75%) in animals who died of hepatic coma. As far as the putative toxins are concerned, significant differences were found between animals undergoing 4 and those undergoing 6 hr of ischemia, especially in the plasma ammonia levels and the plasma ratios for tyrosine and phenylalanine. Plasma arginine levels had fallen to zero in both groups at 24 hr and only rose to preischemic values in animals who survived. This large animal model fulfills the accepted criteria of potential reversibility, reproducibility, and death due to hepatic failure.

References (20)

  • K.A. Harris et al.

    Tolerance of the liver to ischemia in the pig

    J. Surg. Res.

    (1982)
  • W.M. Frederiks et al.

    A model for provoking ischemic necrosis in rat liver parenchyma and its quantitive analysis

    Exp. Pathol.

    (1982)
  • D.J. Miller et al.

    An animal model of fulminant hepatic failure: A feasibility study

    Gastroenterology

    (1976)
  • B. Giges et al.

    Experimental hepatic coma

    Surg. Gynecol. Obstet.

    (1953)
  • K. Tonnesen

    Total devascularisation of the liver: An experimental model of acute liver failure

    Scand. J. Gastroenterol.

    (1976)
  • A.M. Rappaport et al.

    Hepatic coma following ischemia of the liver

    Surg. Gynecol. Obstet.

    (1953)
  • J. Terblanche et al.

    Animal experience with support systems: Are they appropriate animal models of fulminant hepatic necrosis?

  • M.K. Misra et al.

    Acute hepatic coma: A canine model

    Surgery

    (1972)
  • M. Fischer et al.

    Acute liver failure due to temporary hepatic ischemia in the pig

    Acta Hepato-Gastroenterol.

    (1976)
  • C. Battersby et al.

    Liver function in the pig: 1. The effects of 30 minutes normothermic ischemia

    Brit. J. Surg.

    (1974)
There are more references available in the full text version of this article.

Cited by (45)

  • Development of a porcine model of post-hepatectomy liver failure

    2011, Journal of Surgical Research
    Citation Excerpt :

    To prove the functional support of liver support devices in POLF, it is necessary to establish a standardized hepatic failure model, which closely correlates to the real clinical setting and can be reproduced in large animals. The animal models of POLF include devascularization procedures [3], partial or total hepatectomy [4], partial or complete devascularisation [5], with or without portocaval shunt [6, 7]. Terblanche and Hickman [8], with some later additions by others, have established a series of requirements for an ideal model of fulminant hepatic failure (FHF).

  • Rabbit hemorrhagic viral disease: Characterization of a new animal model of fulminant liver failure

    2003, Journal of Laboratory and Clinical Medicine
    Citation Excerpt :

    Although many animal models of FLF are available, most do not meet all these criteria.13,14 Models based on hepatectomy or complete ischemia5,6 lack the potential for reversibility or recovery and do not produce an environment complicated by the release of inflammatory mediators and products of liver-cell necrosis. Agents such as acetaminophen/buthionine sulfoximine or galactosamine7,10,11 produce clinical relevant features, including hypoglycemia, encephalopathy and increased concentrations of liver enzymes, but may require repeated administration, close monitoring of drug levels, and supportive therapy; several factors may cause variability from experiment to experiment.

View all citing articles on Scopus

Supported by The Foundation for Medical Research FUNGO, The Netherlands.

View full text